๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immunotherapy
Clinical trial register · China

Immunotherapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 18 Beijing 14 Shanghai 14 Chengdu 9 Fuzhou 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University7 West China Hospital6 Fudan University5 Cancer Institute and Hospital, Chinese Academy of Medical Sciences4 Nanfang Hospital, Southern Medical University4
Site location
Guangzhou18 Beijing14 Shanghai14 Chengdu9 Fuzhou6
All 36 locations
Target enrolment
to

Immunotherapy trials in China

94 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
NCT07686640Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy
Shandong Cancer Hospital and Institute
Phase 3
180
Jinan
2026-08-15
Not yet open
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
NCT07715565Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
West China Hospital
Phase 2
66
Chengdu
2026-08
Recruiting
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
NCT07113275Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, Immunotherapy
Tao Zhang
Phase 3
444
Wuhan
2026-05-15
Recruiting
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
NCT07668037Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2026-05-01
Recruiting
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
NCT07538479Solid Tumors, Solid Malignancies, Cold Exposure, Immunotherapy
West China Hospital
Phase 1
24
Chengdu
2026-04-20
Recruiting
Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment
NCT07565532Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment
Shanghai Chest Hospital
Observational
500
Shanghai
2026-04-01
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403Bladder Cancer, Liquid Biopsy, Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Not yet open
Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)
NCT07396116Soft Tissue Sarcoma (STS), Retroperitoneal Sarcoma, Immunotherapy, Radiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
28
Beijing
2026-02-12
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
A Pilot Study Evaluating ฮฒ-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
NCT07239466Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
Tao Zhang
Phase 2
25
Wuhan
2026-01-01
Recruiting
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
NCT07669220Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
76
Guangzhou
2026-01-01
Recruiting
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
NCT07436845Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
90
Guangzhou
2025-12-01
Recruiting
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
NCT07261683Ovarian Cancer, Immunotherapy, Pembrolizumab
Obstetrics & Gynecology Hospital of Fudan University
Phase 2
20
Shanghai
2025-12
Recruiting
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
NCT07289997AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Not yet open
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT07131501Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
NCT07085234Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-07-30
Not yet open
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC
NCT07070713Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy
Fujian Cancer Hospital
Phase 2
44
Fuzhou
2025-07-30
Recruiting
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
NCT07165847Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Recruiting
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
NCT07212933Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy
Chinese PLA General Hospital
Phase 2
90
Beijing
2025-07-01
Not yet open
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
NCT06848439Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
Jiangsu Cancer Institute & Hospital
Phase 2
26
Nanjing
2025-06-15
Active, closed
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
NCT07010120HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
NCT06985485Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
The First Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2025-05-17
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
NCT07291921Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003Lung Cancer, Non-Small Cell, Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Beijing
2025-04-20
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT06915389Gastric Cancer, Immunotherapy, Adverse Event, Metabonomics
Qinghai Red Cross Hospital
Observational
100
Xining
2025-02-22
Recruiting
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NCT06738160NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy
Fudan University
Phase 2
27
Shanghai
2025-02-15
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
NCT06964568Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
452
Shanghai
2025-02-01
Recruiting
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
NCT06849193Unresectable Biliary Tract Cancer, Dynamic Prediction Model, Immunotherapy
Zhongda Hospital
Observational
332
Nanjing
2025-01-31
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT06768307SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Recruiting
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
NCT07069842Gastric Cancer, Immunotherapy
Changzhi People's Hospital Affiliated to Changzhi Medical College
Observational
170
Changzhi
2025-01-01
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Recruiting
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
NCT06741982HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1
21
Chengdu
2024-12-15
Active, closed
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
NCT07046195Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
250
Guangzhou
2024-12-11
Recruiting
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy
NCT06946745Immunotherapy
jianming xu
Observational
50
Beijing
2024-12-02
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
West China Hospital
Phase 3
184
Chengdu
2024-11-19
Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
NCT06676722Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Recruiting
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
NCT06826079Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
86
Wuhan
2024-11-01
Recruiting
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
NCT06676449Esophageal Carcinoma, Radiotherapy, Immunotherapy
Fudan University
Phase 3
432
Shanghai
2024-11-01
Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
NCT06702826Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
Rongrong Zhou
Phase 2
20
Changsha
2024-11-01
Not yet open
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
NCT06600841Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Fujian Cancer Hospital
Phase 2
37
Fuzhou
2024-10-01
Active, closed
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
NCT07230080HCC - Hepatocellular Carcinoma, SBRT, TACE, Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
NCT06542796Hepatocellular Carcinoma, Immunotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Not yet open
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
NCT06523049Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
Hao Zeng
Phase 2
67
Chengdu
2024-08
Recruiting
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
NCT06608160PET / CT, Lung Carcinoma, Immunotherapy
Ruijin Hospital
Observational
30
Shanghai
2024-06-20
Recruiting
Nutrition Impact on Immunotherapy of Cancer
NCT06500234Nutrition Disorders, Immunotherapy, Cancer, Survival, Prosthesis
Qingdao Central Hospital
Phase 3
300
Qingdao
2024-06-01
Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
Zhejiang Cancer Hospital
Phase 2
191
Hangzhou
2024-06-01
Recruiting
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy
Hunan Province Tumor Hospital
Phase 2
78
Changsha
2024-05-29
Recruiting
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
NCT06061276Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
Sun Yat-sen University
Not applicable
40
Guanzhou
2024-05-20
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
Recruiting
Adebrelimab ยฑInduction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
NCT06510660Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
Fujian Medical University Union Hospital
Phase 2
48
Fuzhou
2024-04-11
Recruiting
Fruquintinib Combined With Sintilimab ยฑ Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT06356584Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
Shandong Cancer Hospital and Institute
Phase 2
62
Jinan
2024-04-01
Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-03-13
Recruiting
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Recruiting
Immunotherapy for Hepatocellular Carcinoma
NCT06241326Hepatocellular Carcinoma, Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Observational
11,000
Nanjing
2024-03-01
Recruiting
Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
NCT06276088Immunotherapy, Hyperprogression, Biomarker
Nanfang Hospital, Southern Medical University
Observational
374
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-18
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
NCT06256224Cervical Cancer, Chemoradiotherapy, Immunotherapy
Ruijin Hospital
Not applicable
150
Shanghai
2024-02-02
Active, closed
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677Colon Cancer, Mismatch Repair Deficiency, Immunotherapy
Peking Union Medical College Hospital
Phase 2
18
Beijing
2024-01-01
By invitation
Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults
NCT06777173Chronic Hepatitis b, Immunotherapy
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
Recruiting
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
NCT06093438Cervical Cancer, Induction Chemotherapy, Immunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2023-11-01
Recruiting
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
NCT06165900Stereotactic Radiotherapy, Immunotherapy, Breast Cancer
Shengjing Hospital
Phase 2
136
Shenyang
2023-09-26
Recruiting
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
NCT06603402Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy
Sichuan University
Phase 2
41
Chengdu
2023-08-24
Recruiting
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259Malignant Tumor, Immunotherapy, Artificial Intelligence
Xinqiao Hospital of Chongqing
Observational
120
Chongqing
2023-08-10
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Recruiting
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
NCT05967910Esophageal Cancer, Immunotherapy
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-05-01
Recruiting
Adjuvant Chemotherapy Combined With Camrelizumab for โ…กA -โ…ขA NSCLC Patients
NCT05825443Immunotherapy, Chemotherapy
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Recruiting
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
NCT05613478Hepatocellular Carcinoma, Immunotherapy, Preoperative
The First Affiliated Hospital with Nanjing Medical University
Phase 3
130
Nanjing
2023-01-31
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Recruiting
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
NCT05354375Immunotherapy
The Affiliated Hospital of Xuzhou Medical University
Phase 1
20
Xuzhou
2022-12-01
Active, closed
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
NCT05621707Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
Shanghai Chest Hospital
Phase 2
50
Shanghai
2022-11-02
Recruiting
A Exploratory Study of Vฮณ2Vฮด2 T Lymphocyte-based Immunotherapy for MDR-TB
NCT05493267MDR-TB, Immunotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
30
Shanghai
2022-08-03
Recruiting
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
NCT06391190Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
RenJi Hospital
Phase 1/2
20
Shanghai
2022-01-01
Active, closed
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
NCT05176002Esophageal Neoplasm, Immunotherapy, Radiotherapy
Fujian Medical University Union Hospital
Phase 1/2
25
Fuzhou
2021-11-10
Recruiting
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
NCT04969354Immunotherapy
The Affiliated Hospital of Xuzhou Medical University
Phase 1
20
Xuzhou
2021-10-01
Not yet open
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
NCT04890522Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Active, closed
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
NCT04706598Urinary Bladder Neoplasms, Immunotherapy
Fudan University
Phase 1/2
25
Shanghai
2021-06-09
Active, closed
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT04521153Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
Shanghai Zhongshan Hospital
Phase 2/3
294
Shanghai
2021-03-25
Recruiting
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NCT04688801Esophageal Cancer, Gastroesophageal Cancer, Immunotherapy, Adjuvant
The Second Hospital of Shandong University
Not applicable
200
Jinan
2020-07-01
By invitation
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
NCT06849362Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy
Yue Gou
Observational
200
Changsha
2019-12-01
Recruiting
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
NCT04286841Immunotherapy, Lung Cancer
Guangdong Association of Clinical Trials
Observational
100
Guangzhou
2019-05-01
Recruiting
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
Peking University First Hospital
Phase 2
30
Beijing
2019-01-01
Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
NCT03198052Lung Cancer, Cancer, Immunotherapy, CAR-T Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Rows per page Showing 1–94 of 94
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/immunotherapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 94 of those studies listing the condition Immunotherapy.

How many Immunotherapy trials are recruiting in China?

73 of the 94 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 8 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immunotherapy), 94 studies
PhaseStudiesRecruitingShare
Phase 2402942.6%
Observational201721.3%
Not applicable979.6%
Phase 1888.5%
Phase 3888.5%
Phase 1/2636.4%
Phase 2/3202.1%
Phase 4111.1%

Most active sponsors

Lead sponsors with the most studies (Immunotherapy)
Lead sponsorStudiesRecruiting
Sun Yat-sen University76
West China Hospital64
Fudan University54
Cancer Institute and Hospital, Chinese Academy of Medical Sciences43
Nanfang Hospital, Southern Medical University43
Shandong Cancer Hospital and Institute33
The First Affiliated Hospital with Nanjing Medical University32
Fujian Cancer Hospital20
Fujian Medical University Union Hospital21
Guangzhou FineImmune Biotechnology Co., LTD.22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.